Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by R. J. Schilder
Phase II Study of Gefitinib in Patients With Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study
Clinical Cancer Research
Cancer Research
Oncology
mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary
Clinical Cancer Research
Cancer Research
Oncology
Related publications
Phase II Evaluation of Dasatinib in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
A Phase II Evaluation of Lapatinib in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
Phase II Study of Bevacizumab and Pemetrexed for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
A Phase II Evaluation of Nintedanib (BIBF-1120) in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
A Phase 2 Study of Alisertib (MLN8237) in Recurrent or Persistent Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study 0231D
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
Phase II Trial of Nab-Paclitaxel in the Treatment of Recurrent or Persistent Advanced Cervix Cancer: A Gynecologic Oncology Group Study
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
Cetuximab and Platinum-Based Chemoradio- Or Chemotherapy of Patients With Epidermal Growth Factor Receptor Expressing Adenoid Cystic Carcinoma: A Phase II Trial
British Journal of Cancer
Cancer Research
Oncology
Phase II Study of Intermediate-Dose Cytarabine in Patients With Relapsed or Refractory Ewing Sarcoma: A Report From the Children's Oncology Group
Pediatric Blood and Cancer
Oncology
Child Health
Hematology
Perinatology
Medicine
Pediatrics
A Phase II Evaluation of Selumetinib (AZD6244, ARRY-142886), a Selective MEK-1/2 Inhibitor in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
Gynecologic Oncology
Gynecology
Oncology
Obstetrics